UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 279

Sortiert nach

How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?

Journal of Clinical Biochemistry and Nutrition, 2018, Vol.62(1), pp.20-38

2018

Volltextzugriff (PDF)

Baseline characteristics of patients from ongoing post‐marketing surveillance, evaluating the real‐world efficacy and safety of edaravone, a novel, free radical scavenger, for amyotrophic lateral sclerosis patients in Japan (SUNRISE Japan)

Neurology and clinical neuroscience, 2020-09, Vol.8 (5), p.261-269

2020

Volltextzugriff (PDF)

Mechanisms to avoid photoinhibition in a desiccation-tolerant cyanobacterium, Nostoc commune

Plant and cell physiology, 2008-03, Vol.49 (3), p.488-492

2008

Volltextzugriff (PDF)

Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis

International journal of hematology, 2003-07, Vol.78 (1), p.56-61

2003

Volltextzugriff (PDF)

Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

Lancet neurology, 2017-07, Vol.16 (7), p.505-512

2017

Volltextzugriff (PDF)

The YXXQ motif in gp 130 is crucial for STAT3 phosphorylation at Ser727 through an H7-sensitive kinase pathway

Oncogene, 2001-06, Vol.20 (27), p.3464-3474

2001

Volltextzugriff (PDF)

Food Effect Study to Assess the Impact on Edaravone Pharmacokinetic Profiles in Healthy Participants

Clinical therapeutics, 2022-12, Vol.44 (12), p.1552-1565

2022

Volltextzugriff (PDF)

Deactivation of photosynthetic activities is triggered by loss of a small amount of water in a desiccation-tolerant cyanobacterium, Nostoc commune

Plant and cell physiology, 2004-07, Vol.45 (7), p.872-878

2004

Volltextzugriff (PDF)

An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe

Amyotrophic lateral sclerosis and frontotemporal degeneration, 2017-10, Vol.18 (sup1), p.88-97

2017

Volltextzugriff (PDF)

Phase 3, open-label, multicenter safety study of oral edaravone in patients with amyotrophic lateral sclerosis (MT-1186-A01): 48-week results

Journal of the neurological sciences, 2023-12, Vol.455, p.121718, Article 121718

2023

Volltextzugriff (PDF)

Phase 3B study evaluating superiority of daily dosing vs approved on/off oral edaravone dosing over 48 weeks in patients with amyotrophic lateral sclerosis (MT-1186-A02)

Journal of the neurological sciences, 2023-12, Vol.455, p.121719, Article 121719

2023

Volltextzugriff (PDF)

Long‐term safety of oral edaravone in Japanese patients with amyotrophic lateral sclerosis: Sub‐analysis of a global, open‐label, phase 3 study

Neurology and clinical neuroscience, 2024-03, Vol.12 (2), p.95-99

2024

Volltextzugriff (PDF)

Pharmacokinetics of edaravone oral suspension in patients with amyotrophic lateral sclerosis

Clinical therapeutics, 2023-12, Vol.45 (12), p.1251-1258

2023

Volltextzugriff (PDF)

Phase 3B extension study evaluating superiority of daily vs approved on/off oral edaravone dosing in patients with amyotrophic lateral sclerosis

Journal of the neurological sciences, 2023-12, Vol.455, p.121720, Article 121720

2023

Volltextzugriff (PDF)

Subcutaneous panniculitis-like T-cell lymphoma: successful initial treatment with prednisolone and cyclosporin A

Internal medicine (Tokyo, 1992), 2006-01, Vol.45 (1), p.21-24

2006

Volltextzugriff (PDF)

Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment

Muscle & nerve, 2023-02, Vol.67 (2), p.124-129

2023

Volltextzugriff (PDF)

Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48weeks of treatment

Muscle & nerve, 2023-02, Vol.67 (2), p.124-129

2023

Volltextzugriff (PDF)

Azacitidine (AZA) Combination Therapy with Low-Dose AraC for Aggressive Type MDS, Overt AML, and AML Patients

Blood, 2015-12, Vol.126 (23), p.1688-1688

2015

Volltextzugriff (PDF)

Edaravone Administered Orally and Via Nasogastric Tube in Healthy Adults: A Comparative Bioavailability Phase 1 Study

Clinical pharmacology in drug development, 2023-01, Vol.12 (1), p.77-84

2023

Volltextzugriff (PDF)

Stereoselective synthesis of optically active perhydrofuro[2,3- b]furan derivatives

Tetrahedron letters, 2001-07, Vol.42 (28), p.4653-4656

2001

Volltextzugriff (PDF)

Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects

Clinical pharmacology in drug development, 2021-10, Vol.10 (10), p.1188-1197

2021

Volltextzugriff (PDF)

Crystal growth of Ba2Can−1CunO2n(O,F)2 (n = 3 and 4) multi-layered superconductors under high pressure

Superconductor science & technology, 2004-01, Vol.17 (1), p.143-147

2004

Volltextzugriff (PDF)

Analysis of elderly patients with diffuse large B-cell lymphoma: aggressive therapy is a reasonable approach for 'unfit' patients classified by comprehensive geriatric assessment

European journal of haematology, 2016-04, Vol.96 (4), p.409-416

2016

Volltextzugriff (PDF)

Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis and frontotemporal degeneration, 2017-10, Vol.18 (sup1), p.55-63

2017

Volltextzugriff (PDF)

Azacitidine (AZA) Combination Therapy with Low-Dose AraC Is Well Tolerated and Highly Effective for MDS with Overt Leukemia

Blood, 2014-12, Vol.124 (21), p.3260-3260

2014

Volltextzugriff (PDF)

1 – 25 von 279

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(235)
Mit Volltextzugriff
(264)

Publikationsform

Sprache

Englisch
(237)
Japanisch
(114)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?

Baseline characteristics of patients from ongoing post‐marketing surveillance, evaluating the real‐world efficacy and safety of edaravone, a novel, free radical scavenger, for amyotrophic lateral sclerosis patients in Japan (SUNRISE Japan)

Mechanisms to avoid photoinhibition in a desiccation-tolerant cyanobacterium, Nostoc commune

Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis

Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

The YXXQ motif in gp 130 is crucial for STAT3 phosphorylation at Ser727 through an H7-sensitive kinase pathway

Food Effect Study to Assess the Impact on Edaravone Pharmacokinetic Profiles in Healthy Participants

Deactivation of photosynthetic activities is triggered by loss of a small amount of water in a desiccation-tolerant cyanobacterium, Nostoc commune

An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe

Phase 3, open-label, multicenter safety study of oral edaravone in patients with amyotrophic lateral sclerosis (MT-1186-A01): 48-week results

Phase 3B study evaluating superiority of daily dosing vs approved on/off oral edaravone dosing over 48 weeks in patients with amyotrophic lateral sclerosis (MT-1186-A02)

Long‐term safety of oral edaravone in Japanese patients with amyotrophic lateral sclerosis: Sub‐analysis of a global, open‐label, phase 3 study

Pharmacokinetics of edaravone oral suspension in patients with amyotrophic lateral sclerosis

Phase 3B extension study evaluating superiority of daily vs approved on/off oral edaravone dosing in patients with amyotrophic lateral sclerosis

Subcutaneous panniculitis-like T-cell lymphoma: successful initial treatment with prednisolone and cyclosporin A

Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment

Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48weeks of treatment

Azacitidine (AZA) Combination Therapy with Low-Dose AraC for Aggressive Type MDS, Overt AML, and AML Patients

Edaravone Administered Orally and Via Nasogastric Tube in Healthy Adults: A Comparative Bioavailability Phase 1 Study

Stereoselective synthesis of optically active perhydrofuro[2,3- b]furan derivatives

Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects

Crystal growth of Ba2Can−1CunO2n(O,F)2 (n = 3 and 4) multi-layered superconductors under high pressure

Analysis of elderly patients with diffuse large B-cell lymphoma: aggressive therapy is a reasonable approach for 'unfit' patients classified by comprehensive geriatric assessment

Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis

Azacitidine (AZA) Combination Therapy with Low-Dose AraC Is Well Tolerated and Highly Effective for MDS with Overt Leukemia

Suchergebnisse filtern